Overall, modulation of PI3K/Akt signaling by lncRNAs occurs in prostate cancer [215], and therapeutic targeting of lncRNAs, using pharmacological or genetic interventions, can result in cancer inhibition. The gene discussed is AKT1; the disease is prostate cancer.